These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 34276690)

  • 1. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.
    Domblides C; Rochefort J; Riffard C; Panouillot M; Lescaille G; Teillaud JL; Mateo V; Dieu-Nosjean MC
    Front Immunol; 2021; 12():698604. PubMed ID: 34276690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy.
    Langouo Fontsa M; Padonou F; Willard-Gallo K
    Expert Rev Clin Immunol; 2024 Aug; 20(8):839-847. PubMed ID: 39007892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.
    Filderman JN; Appleman M; Chelvanambi M; Taylor JL; Storkus WJ
    Front Immunol; 2021; 12():690105. PubMed ID: 34054879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
    Trüb M; Zippelius A
    Front Immunol; 2021; 12():674565. PubMed ID: 34054861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling.
    Johansson-Percival A; Ganss R
    Front Immunol; 2021; 12():674375. PubMed ID: 34122434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tertiary lymphoid structures in the era of cancer immunotherapy.
    Sautès-Fridman C; Petitprez F; Calderaro J; Fridman WH
    Nat Rev Cancer; 2019 Jun; 19(6):307-325. PubMed ID: 31092904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
    Tang H; Qiu X; Timmerman C; Fu YX
    Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.
    Rodriguez AB; Engelhard VH
    Cancer Immunol Res; 2020 Nov; 8(11):1338-1345. PubMed ID: 33139300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?
    Teillaud JL; Dieu-Nosjean MC
    Front Immunol; 2017; 8():830. PubMed ID: 28785261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Associated Tertiary Lymphoid Structures: A Cancer Biomarker and a Target for Next-generation Immunotherapy.
    Dieu-Nosjean MC
    Adv Exp Med Biol; 2021; 1329():51-68. PubMed ID: 34664233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
    Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
    Front Immunol; 2021; 12():629519. PubMed ID: 33746966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tertiary lymphoid structures in cancer: maturation and induction.
    Chen Y; Wu Y; Yan G; Zhang G
    Front Immunol; 2024; 15():1369626. PubMed ID: 38690273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
    Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating Tumor-Associated Tertiary Lymphoid Structures in Murine Lung Adenocarcinoma.
    Connolly KA; Nader M; Joshi N
    Methods Mol Biol; 2018; 1845():259-273. PubMed ID: 30141018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mature tertiary lymphoid structures: important contributors to anti-tumor immune efficacy.
    Bao X; Lin X; Xie M; Yao J; Song J; Ma X; Zhang X; Zhang Y; Liu Y; Han W; Liang Y; Hu H; Xu L; Xue X
    Front Immunol; 2024; 15():1413067. PubMed ID: 39026670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer.
    Sofopoulos M; Fortis SP; Vaxevanis CK; Sotiriadou NN; Arnogiannaki N; Ardavanis A; Vlachodimitropoulos D; Perez SA; Baxevanis CN
    Cancer Immunol Immunother; 2019 Nov; 68(11):1733-1745. PubMed ID: 31598757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tertiary lymphoid structures associated with enhanced anti-tumor immunity and favorable prognosis in cervical squamous carcinoma.
    Xiong G; Shan J; Chong Q; Cui Y
    Aging (Albany NY); 2024 Apr; 16(8):6898-6920. PubMed ID: 38709170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of tertiary lymphoid structures in cancer.
    You X; Koop K; Weigert A
    Front Immunol; 2023; 14():1286850. PubMed ID: 38111571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients.
    Houel A; Foloppe J; Dieu-Nosjean MC
    Semin Immunol; 2023 Sep; 69():101796. PubMed ID: 37356421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of tertiary lymphoid structure formation: cooperation between inflammation and antigenicity.
    Khanal S; Wieland A; Gunderson AJ
    Front Immunol; 2023; 14():1267654. PubMed ID: 37809103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.